scPharmaceuticals (NASDAQ:SCPH - Get Free Report) released its quarterly earnings results on Wednesday. The company reported ($0.35) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.05, Zacks reports. The company had revenue of $12.15 million during the quarter, compared to the consensus estimate of $12.08 million. scPharmaceuticals had a negative return on equity of 244.93% and a negative net margin of 264.60%.
scPharmaceuticals Trading Down 0.3 %
Shares of SCPH stock traded down $0.01 during mid-day trading on Friday, hitting $3.00. 571,430 shares of the company's stock were exchanged, compared to its average volume of 325,319. scPharmaceuticals has a fifty-two week low of $2.75 and a fifty-two week high of $5.65. The stock has a 50-day simple moving average of $3.27 and a two-hundred day simple moving average of $3.78. The company has a quick ratio of 6.89, a current ratio of 8.08 and a debt-to-equity ratio of 1.66. The stock has a market cap of $150.85 million, a price-to-earnings ratio of -1.58 and a beta of 0.40.
Wall Street Analysts Forecast Growth
SCPH has been the subject of several recent research reports. HC Wainwright reissued a "buy" rating and set a $18.00 price target on shares of scPharmaceuticals in a research report on Thursday. Maxim Group decreased their price objective on scPharmaceuticals from $20.00 to $12.00 and set a "buy" rating on the stock in a report on Thursday.
View Our Latest Stock Analysis on SCPH
About scPharmaceuticals
(
Get Free Report)
scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.
See Also
Before you consider scPharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and scPharmaceuticals wasn't on the list.
While scPharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
